Cover Image
市場調查報告書

慢性發炎:開發中產品分析

Chronic Inflammation - Pipeline Review, H1 2014

出版商 Global Markets Direct 商品編碼 271842
出版日期 內容資訊 英文 61 Pages
訂單完成後即時交付
價格
Back to Top
慢性發炎:開發中產品分析 Chronic Inflammation - Pipeline Review, H1 2014
出版日期: 2014年05月21日 內容資訊: 英文 61 Pages
簡介

慢性發炎定義為相較下較快速或緩慢,在不知不覺間(數週、數月甚至數年)進行的發炎。症狀有疼痛、皮膚發紅、不動狀態、腫、發燒等。

本報告提供慢性發炎治療藥開發狀況調查分析,提供開發平台產品概要、臨床實驗階段別產品概要、再加上主要企業簡介、藥劑簡介、平台產品最新趨勢、最新消息與新聞等有體系之資訊。

目錄

簡介

慢性發炎概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

研究中的治療藥:大學/研究機關別

開發中產品概要

  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

研究中的產品:大學/研究機關別

開發治療藥的企業

  • Actelion Ltd
  • Incyte Corporation
  • Italfarmaco S.p.A.
  • Phenex Pharmaceuticals AG
  • Ventria Bioscience
  • Anacor Pharmaceuticals, Inc.
  • Dynamis Therapeutics, Inc.
  • Dompe Farmaceutici S.p.A.
  • InnaVirVax SA
  • Istituto Italiano di Tecnologia

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各類型分子

藥物簡介

  • Drug for Chronic Inflammatory Condition
  • ACT-389949
  • DF-2156A
  • Retinoid-Acid Receptor Related Orphan Receptor Gamma T Program
  • Selective Inhibitor of Pro Inflammatory Cytokine
  • AN-3485
  • Monoclonal Antibody to Antagonize Alpha Epsilon Beta 7 Integrin for Chronic Inflammation
  • DYN-15
  • Monocalnal Antibody for Chronic Inflammation
  • TAT-SNAP-23
  • NS-4
  • Anti-S100A9 Monoclonal Antibody
  • MCP-1
  • Synthetic Peptides to Inhibit TACE for Chronic Inflammation
  • Inactive Plasmin
  • VAC-03
  • N-Acylethanolamine Acid Amidase Inhibitors for Chronic Inflammation and Atopic Dermatitis
  • Antibody to Inhibit M-DC8 Positive Monocyte for Chronic Inflammatory Diseases
  • VEN-150

暫停的計劃

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC4948IDB

Global Markets Direct's, 'Chronic Inflammation - Pipeline Review, H1 2014', provides an overview of the Chronic Inflammation's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chronic Inflammation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Inflammation and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Chronic Inflammation
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Chronic Inflammation and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Chronic Inflammation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Chronic Inflammation pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Chronic Inflammation
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Chronic Inflammation pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Chronic Inflammation Overview
  • Therapeutics Development
    • Pipeline Products for Chronic Inflammation - Overview
    • Pipeline Products for Chronic Inflammation - Comparative Analysis
  • Chronic Inflammation - Therapeutics under Development by Companies
  • Chronic Inflammation - Therapeutics under Investigation by Universities/Institutes
  • Chronic Inflammation - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Chronic Inflammation - Products under Development by Companies
  • Chronic Inflammation - Products under Investigation by Universities/Institutes
  • Chronic Inflammation - Companies Involved in Therapeutics Development
    • Actelion Ltd
    • Incyte Corporation
    • Italfarmaco S.p.A.
    • Phenex Pharmaceuticals AG
    • Ventria Bioscience
    • Anacor Pharmaceuticals, Inc.
    • Dynamis Therapeutics, Inc.
    • Dompe Farmaceutici S.p.A.
    • InnaVirVax SA
    • Istituto Italiano di Tecnologia
  • Chronic Inflammation - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Drug for Chronic Inflammatory Condition - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ACT-389949 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DF-2156A - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Retinoid-Acid Receptor Related Orphan Receptor Gamma T Program - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Selective Inhibitor of Pro Inflammatory Cytokine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AN-3485 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize Alpha Epsilon Beta 7 Integrin for Chronic Inflammation - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DYN-15 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monocalnal Antibody for Chronic Inflammation - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TAT-SNAP-23 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NS-4 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Anti-S100A9 Monoclonal Antibody - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MCP-1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptides to Inhibit TACE for Chronic Inflammation - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Inactive Plasmin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VAC-03 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • N-Acylethanolamine Acid Amidase Inhibitors for Chronic Inflammation and Atopic Dermatitis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antibody to Inhibit M-DC8 Positive Monocyte for Chronic Inflammatory Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VEN-150 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Chronic Inflammation - Dormant Projects
  • Chronic Inflammation - Product Development Milestones
    • Featured News & Press Releases
      • Apr 03, 2014: Glenmark's Novel Molecule 'GRC 27864' for Chronic Inflammatory Diseases Including Pain Entering Human Trials
      • Feb 20, 2014: La Jolla Pharmaceutical Company Receives Notice of Allowance for Patent Claims Covering Modified Pectin for Treatment of Chronic Inflammation
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Chronic Inflammation, H1 2014
  • Number of Products under Development for Chronic Inflammation - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Development, H1 2014
  • Products under Development by Companies, H1 2014
  • Products under Investigation by Universities/Institutes, H1 2014
  • Chronic Inflammation - Pipeline by Actelion Ltd, H1 2014
  • Chronic Inflammation - Pipeline by Incyte Corporation, H1 2014
  • Chronic Inflammation - Pipeline by Italfarmaco S.p.A., H1 2014
  • Chronic Inflammation - Pipeline by Phenex Pharmaceuticals AG, H1 2014
  • Chronic Inflammation - Pipeline by Ventria Bioscience, H1 2014
  • Chronic Inflammation - Pipeline by Anacor Pharmaceuticals, Inc., H1 2014
  • Chronic Inflammation - Pipeline by Dynamis Therapeutics, Inc., H1 2014
  • Chronic Inflammation - Pipeline by Dompe Farmaceutici S.p.A., H1 2014
  • Chronic Inflammation - Pipeline by InnaVirVax SA, H1 2014
  • Chronic Inflammation - Pipeline by Istituto Italiano di Tecnologia, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Stage and Target, H1 2014
  • Number of Products by Stage and Mechanism of Action, H1 2014
  • Number of Products by Stage and Route of Administration, H1 2014
  • Number of Products by Stage and Molecule Type, H1 2014
  • Chronic Inflammation - Dormant Projects, H1 2014

List of Figures

  • Number of Products under Development for Chronic Inflammation, H1 2014
  • Number of Products under Development for Chronic Inflammation - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Comparative Analysis by Early Stage Products, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Top 10 Target, H1 2014
  • Number of Products by Stage and Top 10 Target, H1 2014
  • Number of Products by Top 10 Mechanism of Action, H1 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
  • Number of Products by Top 10 Route of Administration, H1 2014
  • Number of Products by Stage and Top 10 Route of Administration, H1 2014
  • Number of Products by Top 10 Molecule Type, H1 2014
  • Number of Products by Stage and Top 10 Molecule Type, H1 2014
Back to Top